Techniques in Regional Anesthesia & Pain Management
Volume 13, Issue 1 , Pages 20-27 , January 2009

Daily pharmacologic prophylaxis of episodic migraine

  • Cynthia C. Bamford, MD
    • ,
  • Stewart J. Tepper, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Stewart J. Tepper, MD, Headache Center, T-33, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

References 

  1. International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:1–60
  2. Stewart W, Schecter A, Rasmussen RK. Migraine prevalence (A review of population-based studies). Neurology. 1994;44(suppl):S17–S23
  3. Hu X, Markson L, Lipton R, et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813–818
  4. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 2003;7:359–390
  5. Gursoy-Ozdemir Y, Qiu J, Matsuoka M, et al. Cortical spreading depression activates and up-regulates MMP. J Clin Invest. 2004;113:1447–1455
  6. Cao Y, Aurora SK, Nagesh V, et al. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology. 2002;59:72–78
  7. Woods RP, Iacoboni M, Mazziotta JC. Brief report: Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med. 1994;331:1689–1692
  8. Pietrobon D, Streissing J. Neurobiology of migraine. Nature. 2003;4:386–398
  9. Raskin N, Hosobuchi Y, Lamb S. Headache may arise from perturbation of the brain. Headache. 1987;27:416–420
  10. Weiller C, May A, Limroth V, et al. Brainstem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658–660
  11. May A, Goadsby PJ. The trigeminovascular system in humans: Pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19
  12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346
  13. Dimitriadou V, Theoharides TC. Ultrastructural evidence for neurogenically mediated changes in blood vessels in the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience. 1992;48:187–203
  14. Burstein R, Collins B, Jakubowki M, et al. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26
  15. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22:491–512
  16. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic Migaine: A longitudinal population-based study. Headache. 2008;48:1157–1168
  17. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–661
  18. Heninger FR, Charney DS. Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. In:  Melzer HY editors. Psychopharmacology: The Third Generation of Progress. New York: Raven; 1987;p. 535–544
  19. Peroutka SJ. Developments in 5-Hydroxytriptamine receptor pharmacology. In:  Mathew NT editors. Headache (Neurologic Clinics). vol. 8:Philadelphia, PA: WB Saunders Company; 1990;p. 829–839
  20. Ablad B, Dahlof C. Migraine and beta-blockade: Modulation of sympathetic neurotransmission. Cephalalgia. 1986;6:7–13
  21. Miljanich G, Ramachandran J. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol. 1995;35:707–734
  22. Cutrer F, Moskowitz MA. Possible mechanisms of valproate and neurosteroids in a model of trigeminal pain. Headache. 1997;36:579–585
  23. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307–311
  24. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119–128
  25. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3–S9
  26. Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache. 2000;40:158–163
  27. Mauskopf A, Altura B, Cracco RQ, et al. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines (Possible role for ICa2+/Mg2+ ratio). Headache. 1993;33:135–138
  28. Ramadan N, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache. 1989;29:590–593
  29. Peikert A, WC , Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257–263
  30. Bigal ME, Bordini BC, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura (A randomized, double-blind, placebo-controlled study). Cephalalgia. 2002;22:345–353
  31. Tepper SJ, Bigal M, Rapoport A, et al. Alternative therapies: Evidence based evaluation in migraine. Headache Care. 2006;3:57–64
  32. Sandor PS, DiClemente L, Coppola G, et al. A randomized controlled trial of coenzyme Q10 in migraine prophylaxis. Neurology. 2005;64:713–715
  33. Schoenen J, Jacquy J, Lanaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1998;50:466–470
  34. Fillipi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 2004;113:400–404
  35. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache. 2003;43(suppl 1):S9–S15
  36. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type a: Implications for migraine therapy. Headache. 2004;44:35–42
  37. Ramadan N, Silberstein SD, Freitag FG, et al. Multispecialty consensus on diagnosis and treatment of headache: Pharmacological management for prevention of migraine Neurology, 2000. serial online at: http://www.aan.com/professionals/practice/pdfs/g10090.pdf
  38. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59:1078–1086
  39. Allegran. http://www.allergan.comAccessed September 21, 2008
  40. Lipton RB, Silberstein SD, Saper JR, et al. Why headache treatment fails. Neurology. 2003;60:1064–1070

PII: S1084-208X(09)00002-0

doi: 10.1053/j.trap.2009.03.001

Techniques in Regional Anesthesia & Pain Management
Volume 13, Issue 1 , Pages 20-27 , January 2009

Article Tools

* Image Usage & Resolution